Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31320075 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10KMT2AHPGDMEN1 | |
| SCHEMBL23487150 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10KMT2AHPGDMEN1 | |
| SCHEMBL7841633 | 0.79 | ATM (0.39) | SMN1; SMN2HSD17B10KMT2AHPGDMEN1 | |
| SCHEMBL31008158 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10HPGDALDH1A1OPRK1 | |
| SCHEMBL23695127 | 0.76 | HSD17B10 (0.41) | SMN1; SMN2HSD17B10HRH3KMT2AHPGD | |
| SCHEMBL23695128 | 0.76 | HSD17B10 (0.41) | SMN1; SMN2HSD17B10HRH3KMT2AHPGD | |
| SCHEMBL21679124 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD17B10KMT2AHPGD | |
| SCHEMBL14157186 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD17B10KMT2AHPGD | |
| SCHEMBL24927983 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD17B10KMT2AHPGD | |
| SCHEMBL31368141 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD17B10KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | SMN1; SMN2 1891/4885HSD17B10 2827/4885HRH3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.